Information  X 
Enter a valid email address

EKF Diagnostics Hldg (EKF)

  Print      Mail a friend

Thursday 11 January, 2018

EKF Diagnostics Hldg

Trading update

RNS Number : 5336B
EKF Diagnostics Holdings PLC
11 January 2018


This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).


EKF Diagnostics Holdings plc

("EKF", the "Company")


Trading update


EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, provides shareholders with the following update on current trading.


The Company is pleased to announce that revenues for the year ended 31 December 2017 are in line with expectations whilst adjusted EBITDA is expected to comfortably exceed expectations. Net cash at the year end is £6.8m.


The Company also announces that it intends to spin-out its sTNFR biomarker technology into a separate entity to enable it to exploit opportunities to realise value from this technology, which having been fully impaired and has a current carrying value of nil. sTNFR1/2 (Soluble Tumour Necrosis Factor Receptors 1 and 2) are novel biomarkers used to identify type 1 and type 2 diabetes patients at highest risk of progressive Diabetic Kidney Disease (DKD) potentially leading to End Stage Renal Disease (ESRD). 


The Directors intend to establish a joint venture to develop sTNFR as a routine test for predicting the progression of diabetic patients to ESRD and will make further announcements at the appropriate time.




EKF Diagnostics Holdings plc

Christopher Mills, Non-Executive Chairman

Tel: 029 2071 0570

Julian Baines, CEO 

Richard Evans, FD & COO

N+1 Singer (Nomad & Broker)

Tel: 020 7496 3000

Alex Price / Shaun Dobson / Ali Laughton-Scott

Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303


This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t